Sublingual administration of Δ9-tetrahydrocannabinol/ β-cyclodextrin complex increases the bioavailability of Δ9-tetrahydrocannabinol in rabbits

Life Sciences

Volumn 78, Issue 17, 2006, Pages 1911-1914

  Mannila, Janne ^a   Järvinen, Tomi ^a   Järvinen, Kristiina ^a   Tervonen, Jussi ^a   Jarho, Pekka ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

9 Tetrahydrocannabinol; Bioavailability; Cyclodextrins; Transmucosal

Indexed keywords

ALCOHOL; BETA CYCLODEXTRIN; DRONABINOL; BETA CYCLODEXTRIN DERIVATIVE; EXCIPIENT; TETRAHYDROCANNABINOL;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; MALE; NONHUMAN; RABBIT; ANIMAL; BIOAVAILABILITY; CHEMISTRY; COMPARATIVE STUDY; DRUG ADMINISTRATION ROUTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; SUBLINGUAL DRUG ADMINISTRATION;

ORYCTOLAGUS CUNICULUS;

ADMINISTRATION, ORAL; ADMINISTRATION, SUBLINGUAL; ANIMALS; BETA-CYCLODEXTRINS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ADMINISTRATION ROUTES; EXCIPIENTS; FEMALE; INJECTIONS, INTRAVENOUS; MALE; RABBITS; TETRAHYDROCANNABINOL;

EID: 33644618732     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2005.08.025     Document Type: Article

References (17)

1. J.E. Beal, R. Olson, L. Laubenstein, J.O. Morales, P. Bellman, B. Yangco, L. Lefkowitz, T.F. Plasse, and K.V. Shepard Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS Journal of Pain and Symptom Management 10 2 1995 89 97
2. J.S. Berman, C. Symonds, and R. Birch Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial Pain 112 3 2004 299 306
3. L. Boulmedarat, A. Bochot, S. Lesieur, and E. Fattal Evaluation of buccal methyl-betacyclodextrin toxicity on human oral epithelial cell culture model Journal of Pharmaceutical Sciences 94 6 2005 1300 1309
4. N.A. Darmani, and J.L. Crim Delta-9-tetrahydrocannabinol differentially suppresses emesis versus enhanced locomotor activity produced by chemically diverse dopamine D2/D3 receptor agonists in the least shrew (Cryptotis parva) Pharmacology, Biochemistry and Behavior 80 1 2005 35 44
5. GW Pharma Ltd., 2005. Sativex® Product Monograph (http://www. bayerhealth.com/display.cfm?Object_ID=272&Article_ID=122 ).
6. W. Hall, M. Christie, and D. Currow Cannabinoids and cancer: causation, remediation, and palliation The Lancet Oncology 6 1 2005 35 42
7. T. Irie, and K. Uekama Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation Journal of Pharmaceutical Sciences 86 2 1997 147 162
8. I. Lastres-Becker, F. Molina-Holgado, J.A. Ramos, R. Mechoulam, and J. Fernández-Ruiz Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease Neurobiology of Disease 19 2005 96 107
9. T. Loftsson, and M.E. Brewster Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization Journal of Pharmaceutical Sciences 85 10 1996 1017 1025
10. T. Loftsson, P. Jarho, M. Másson, and T. Järvinen Cyclodextrins in drug delivery Expert Opinion on Drug Delivery 2 2 2005 335 351
11. J. Mannila, M. Lehtonen, T. Jarvinen, and P. Jarho Determination of Delta9-tetrahydrocannabinol from rabbit plasma by gas chromatography-mass spectrometry using two ionization techniques Journal of Chromatography. B 810 2 2004 283 290
12. J. Mannila, T. Järvinen, K. Järvinen, M. Tarvainen, and P. Jarho Effects of RM-beta-CD on sublingual bioavailability of delta-9-tetrahydrocannabinol in rabbits European Journal of Pharmaceutical Sciences 26 1 2005 71 77
13. A. Ohlsson, J.E. Lindgren, A. Wahlen, S. Agurell, L.E. Hollister, and H.K. Gillespie Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking Clinical Pharmacology and Therapeutics 28 3 1980 409 416
14. R.A. Rajewski, and V.J. Stella Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery Journal of Pharmaceutical Sciences 85 11 1996 1142 1169
15. K. Uekama Design and evaluation of cyclodextrin-based drug formulation Chemical and Pharmaceutical Bulletin 52 8 2004 900 915
16. J.A. Weatherell, C. Robinson, and M.J. Rathbone M.J. Rathbone Oral Mucosal Drug Delivery 1996 Marcel Dekker, Inc. Hamilton, New Zealand
17. J. Zajicek, P. Fox, H. Sanders, D. Wright, J. Vickery, A. Nunn, and A. Thompson Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial The Lancet 362 9395 2003 1517 1526